Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Leukemia & Lymphoma
|
November 23, 2022
Central nervous system involvement by mantle cell lymphoma
Nicole McLaughlin, Yucai Wang, Thomas Witzig, et al.
Blood Cancer Journal
|
June 28, 2018
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
Ayed O Ayed, Annalisa Chiappella, Levi Pederson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 1, 2015
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience
Moussab Damlaj, Nanna H Sulai, Jennifer L Oliveira, et al.
Leukemia & Lymphoma
|
July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
Kristine Broglio, Lale Kostakoglu, Carol Ward, et al.
The Oncologist
|
March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
American Journal of Hematology
|
March 20, 2013
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
Taxiarchis V Kourelis, Morie Gertz, Clive Zent, et al.
Blood
|
November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Muhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.
Leukemia & Lymphoma
|
September 17, 2004
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy
Carlo Visco, Theodoros P Vassilakopoulos, Kay Oliver Kliche, et al.
British Journal of Haematology
|
August 27, 2024
CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
Emil Arjun Kumar, Koorosh Korfi, Findlay Bewicke-Copley, et al.
Cancer Reports (Hoboken, N.J.)
|
July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo, Armando Santoro, Guillaume Cartron, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Leukemia & Lymphoma
|
November 23, 2022
Central nervous system involvement by mantle cell lymphoma
Nicole McLaughlin, Yucai Wang, Thomas Witzig, et al.
Blood Cancer Journal
|
June 28, 2018
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
Ayed O Ayed, Annalisa Chiappella, Levi Pederson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 1, 2015
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience
Moussab Damlaj, Nanna H Sulai, Jennifer L Oliveira, et al.
Leukemia & Lymphoma
|
July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
Kristine Broglio, Lale Kostakoglu, Carol Ward, et al.
The Oncologist
|
March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
American Journal of Hematology
|
March 20, 2013
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
Taxiarchis V Kourelis, Morie Gertz, Clive Zent, et al.
Blood
|
November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Muhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.
Leukemia & Lymphoma
|
September 17, 2004
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy
Carlo Visco, Theodoros P Vassilakopoulos, Kay Oliver Kliche, et al.
British Journal of Haematology
|
August 27, 2024
CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
Emil Arjun Kumar, Koorosh Korfi, Findlay Bewicke-Copley, et al.
Cancer Reports (Hoboken, N.J.)
|
July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo, Armando Santoro, Guillaume Cartron, et al.
Page
of 4